Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1
USD
|
+2.04%
|
|
-0.99%
|
-20.00%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,674
|
765.8
|
92.18
|
72.9
|
60.1
|
-
|
-
|
Enterprise Value (EV)
1 |
1,458
|
601.3
|
-146
|
72.9
|
29.58
|
85.27
|
23.18
|
P/E ratio
|
-5.5
x
|
-4.92
x
|
-0.68
x
|
-0.64
x
|
-0.65
x
|
-0.58
x
|
-0.57
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
11.6
x
|
11
x
|
18.4
x
|
-
|
EV / Revenue
|
-
|
-
|
-
|
11.6
x
|
5.4
x
|
26.1
x
|
-
|
EV / EBITDA
|
-25.5
x
|
-4.02
x
|
1.08
x
|
-0.61
x
|
-0.32
x
|
-0.69
x
|
-0.12
x
|
EV / FCF
|
-30.7
x
|
-4.92
x
|
1.6
x
|
-
|
-0.29
x
|
-0.87
x
|
-0.18
x
|
FCF Yield
|
-3.26%
|
-20.3%
|
62.7%
|
-
|
-348%
|
-115%
|
-548%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
56,034
|
56,347
|
56,898
|
58,317
|
60,095
|
-
|
-
|
Reference price
2 |
29.87
|
13.59
|
1.620
|
1.250
|
1.000
|
1.000
|
1.000
|
Announcement Date
|
3/23/21
|
2/24/22
|
3/15/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
6.288
|
5.475
|
3.271
|
-
|
EBITDA
1 |
-
|
-57.2
|
-149.4
|
-134.8
|
-119.7
|
-93.46
|
-122.8
|
-194.6
|
EBIT
1 |
-16.82
|
-58.04
|
-151.4
|
-137.1
|
-121.8
|
-96.1
|
-105.7
|
-177.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-1,937.5%
|
-1,755.25%
|
-3,232.65%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-88.44
|
-151.1
|
-133.2
|
-112.7
|
-92.12
|
-104.4
|
-176.6
|
Net income
1 |
-
|
-88.44
|
-151.1
|
-133.2
|
-112.7
|
-84.95
|
-94.37
|
-151.6
|
Net margin
|
-
|
-
|
-
|
-
|
-1,791.87%
|
-1,551.66%
|
-2,885.27%
|
-
|
EPS
2 |
-3.220
|
-5.430
|
-2.760
|
-2.370
|
-1.950
|
-1.537
|
-1.723
|
-1.760
|
Free Cash Flow
1 |
-
|
-47.48
|
-122.2
|
-91.5
|
-
|
-103
|
-98
|
-127
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-1,881.28%
|
-2,996.33%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/31/20
|
3/23/21
|
2/24/22
|
3/15/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
1.221
|
1.864
|
0.917
|
2.286
|
1
|
1.4
|
1.475
|
1.6
|
2.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-26.87
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-33.67
|
-62.41
|
-36.36
|
-33.53
|
-33.54
|
-33.68
|
-28.49
|
-32.17
|
-33.82
|
-27.34
|
-25.53
|
-24.67
|
-23.2
|
-22.7
|
-14.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,333.58%
|
-1,725.75%
|
-3,688.66%
|
-1,196.15%
|
-2,553.33%
|
-1,761.9%
|
-1,572.88%
|
-1,418.75%
|
-580%
|
Earnings before Tax (EBT)
1 |
-33.6
|
-62.33
|
-36.26
|
-32.9
|
-32.26
|
-31.78
|
-26.24
|
-29.74
|
-31.37
|
-25.32
|
-25.15
|
-23.5
|
-22.05
|
-22.5
|
-13.5
|
Net income
1 |
-33.6
|
-62.33
|
-36.26
|
-32.9
|
-32.26
|
-31.78
|
-26.24
|
-29.74
|
-31.37
|
-25.32
|
-25.15
|
-23.5
|
-22.05
|
-22.5
|
-13.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,148.89%
|
-1,595.55%
|
-3,421.37%
|
-1,107.61%
|
-2,515%
|
-1,678.57%
|
-1,494.92%
|
-1,406.25%
|
-540%
|
EPS
2 |
-0.6100
|
-1.130
|
-0.6500
|
-0.5900
|
-0.5700
|
-0.5600
|
-0.4600
|
-0.5200
|
-0.5400
|
-0.4300
|
-0.4100
|
-0.3933
|
-0.3800
|
-0.3567
|
-0.2200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
2/24/22
|
5/4/22
|
8/4/22
|
11/8/22
|
3/15/23
|
5/10/23
|
8/8/23
|
11/13/23
|
3/21/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
25.2
|
-
|
Net Cash position
1 |
216
|
165
|
238
|
-
|
30.5
|
-
|
36.9
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.205
x
|
-
|
Free Cash Flow
1 |
-47.5
|
-122
|
-91.5
|
-
|
-103
|
-98
|
-127
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
9.57
|
4.26
|
0.58
|
-
|
8
|
9
|
9
|
Capex / Sales
|
-
|
-
|
-
|
-
|
146.12%
|
275.17%
|
-
|
Announcement Date
|
3/23/21
|
2/24/22
|
3/15/23
|
3/21/24
|
-
|
-
|
-
|
Average target price
4.25
USD Spread / Average Target +325.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.00% | 60.1M | | +1.51% | 42.75B | | +48.26% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|